Solana Company (HSDT) Q2 2026 earnings review
Strategic Pivot Complete, But Operational Execution Lags Behind Crypto Volatility
Solana Company has fully transformed into a digital asset holding company by divesting its legacy medical device business. However, the Q2 results reveal a stark reality: the much-touted 'institutional services flywheel' is not yet generating meaningful cash. Total revenue decelerated to $2.5 million from $3.6 million in Q1, driven almost entirely by Solana staking yields. Meanwhile, General & Administrative expenses spiked to $11.1 million (including $6.8 million in severance for the legacy business sale). With 'Other Revenue' sitting at a microscopic $14,000, the company remains completely dependent on the highly volatile price of SOL and staking yields, resulting in a $30.3 million net loss for the quarter.
🐂 Bull Case
The divestiture of the PoNS medical device business is finally complete. While it triggered a painful $6.8 million one-time severance charge, it removes a major non-core structural cost going forward.
The core treasury strategy is working on-chain. The company generated 31.2k SOL in staking rewards in Q2, which are automatically restaked to compound returns, providing steady token accumulation regardless of fiat price.
🐻 Bear Case
Management promised 'relatively significant revenues' from institutional advisory contracts in Q1. In Q2, non-staking revenue was just $14,000. The diversified business model remains theoretical.
Even stripping out the $6.8 million severance charge, base G&A expenses of $4.3 million far outpaced total revenue of $2.5 million. The company is burning operating cash before accounting for crypto volatility.
⚖️ Verdict: 🔴
Bearish. The cleanup of the corporate structure is welcome, but the company's financial results are decelerating. The promised diversification into institutional advisory and infrastructure services has not materialized in the P&L, leaving the stock as a highly dilutive, high-expense proxy for Solana.
Key Themes
The Missing Advisory Revenues
During the Q1 earnings call, management emphatically stated they were signing advisory contracts with APAC financial institutions that would generate 'relatively significant revenues' this year. The Q2 data directly contradicts this optimistic narrative: 'Other Revenue' came in at a dismal $14,000, down from $204,000 in Q1 and $355,000 in Q3 2025. This raises serious red flags about the execution risk of their three-pronged 'flywheel' strategy.
Pacific Backbone Validation Infrastructure Live
A specific technology and infrastructure milestone was reached: the company built out its first institutional validator cluster in Tokyo. Combined with a strategic partnership with the Jito Foundation announced in May (designed to enhance MEV capture and yield optimization), this creates the physical footprint needed to attract third-party institutional SOL delegations in the Asia-Pacific region.
Compounding Staking Yields
Despite fiat revenue decelerating, the underlying token accumulation remains stable. The company earned 31.2k SOL in staking rewards during Q2 (compared to 32.5k in Q1). Because these rewards are automatically restaked, the company benefits from compounding unit growth, even when the U.S. dollar value of those rewards fluctuates.
Extreme Macro Crypto Volatility Dictates the P&L
The company's earnings remain entirely at the mercy of macroeconomic crypto market conditions. A $25.4 million realized loss on digital assets in Q2 drove the bulk of the $32.7 million operating loss. The balance sheet reflects this volatility: total digital asset exposure dropped to $168.3 million, down from $193.8 million in Q1, primarily due to asset price deflation rather than strategic liquidation.
Strategic Divestiture Clears the Deck
The company formally severed ties with its legacy past by divesting the PoNS medical device business. While the accounting impact was messy—a $3.1 million non-operating gain offset by $6.8 million in severance costs hitting G&A—this move transforms HSDT into a pure-play digital asset entity and removes a long-standing drag on management attention and operational cash flow.
Dilutive Accretion Strategy Continues
Management continues to play both sides of the capital markets. In Q2, they completed a registered direct offering led by Mirae Asset, raising $7.9 million. Concurrently, they repurchased $2.3 million in shares (retiring 1.3 million shares). While management claims issuing stock at a premium to NAV to buy SOL is mathematically accretive to 'SOL per share', it undeniably dilutes existing shareholders' percentage ownership of the underlying business.
Other KPIs
Total exposure decelerated from $193.8 million in Q1. The current balance consists of $21.0 million in current digital assets, $112.3 million in long-term digital assets, $18.5 million in restricted assets, and roughly $16.5 million in receivables and fund investments. This sequential decline underscores the impact of the $25.4 million realized loss taken during the quarter.
Expenses accelerated sharply from $5.2 million in Q1. The bulk of this increase was a one-time $6.8 million severance charge related to the PoNS divestiture. Adjusting for this, base G&A sits at roughly $4.3 million—still significantly higher than the $2.5 million in revenue generated during the quarter, highlighting negative core operating leverage.
Guidance
Management did not provide quantitative financial guidance. However, in prior quarters, they guided that the divestiture of the legacy PoNS business would have a 'pretty significant positive impact' on recurring operational costs starting in Q2. Investors should look for base G&A to drop meaningfully in Q3 now that the $6.8 million severance is behind them.
Key Questions
Timeline for Advisory Revenues
In Q1, you indicated you were signing contracts that would generate 'relatively significant revenues' this year. With Q2 'Other Revenue' at just $14,000, has the timeline for these institutional advisory contracts been pushed back, or did deals fall through?
Base Operating Cash Burn
Stripping out the $6.8 million severance charge, your base G&A of roughly $4.3 million still exceeds your staking revenue. What is the normalized quarterly cash burn rate we should expect moving forward, and how long can the balance sheet sustain it without relying on further equity dilution?
Third-Party Validation Delegation
With the Tokyo validator cluster now operational under the Pacific Backbone initiative, when do you expect to begin reporting meaningful third-party SOL delegation metrics, and how is the Jito partnership actively contributing to that pipeline?